Fierce Pharma

JUNE 12, 2023

market without a patent infringement challenge by early 2025 thanks to a new settlement. 21, 2025. Another biosimilar product copying Johnson & Johnson’s top-selling drug Stelara may enter the U.S. Following a deal with Amgen, J&J has granted Alvotech and Teva a license to launch their Stelara biosimilar no later than Feb.

Marketing 259

Marketing 259

Fierce Pharma

AUGUST 23, 2023

In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the succe | In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the success of shingles vaccine Shingrix.

206

206

Fierce Pharma

NOVEMBER 1, 2023

But the new product will not launch until 2025 because of a settlement the companies made earlier this year, which delayed the launch in exchange for J&J dropping a patent infringement lawsuit. The FDA has signed off on Amgen’s biosimilar version of Johnson & Johnson’s autoimmune standout Stelara. |

FDA 239

FDA 239

Fierce Pharma

SEPTEMBER 11, 2023

Versions from Amgen, Teva and Alvotech are expected to launch in early 2025. . | The blockbuster inflammatory med's patents begin to expire this year, leaving biosimilar makers scrambling for a piece of the large market.

Marketing 241

Marketing 241

Fierce Pharma

OCTOBER 24, 2023

The company expects a decision in the first quarter of next year and is making plans to launch the treatment in the 2024-2025 flu season. The FDA has accepted AZ’s supplemental biologics license application (sBLA) for self-administered FluMist Qudrivalent.

FDA 241

FDA Marketing 241

pharmaphorum

MAY 10, 2024

A $650 million programme set up by pharma group MSD to help prevent maternal mortality and improve health equity around the world has reached over 30 million women, easily outpacing its target of 25 million by 2025.

Pharma 57

Pharma Healthcare Healthcare 57

Fierce Pharma

JUNE 29, 2023

Much of that momentum hinges on Sanofi’s pipeline, where the company is targeting an “accelerated pace of innovation” in a bid to launch at least five phase 3 vaccine programs by 2025.

Sales 209

Sales 209

European Pharmaceutical Review

NOVEMBER 3, 2022

Companies intend to report emissions for these trials from 2025. Ensure more than 90 percent of trials starting in 2025 include a review of how digital solutions can lower emissions. The post Seven pharma CEOs unite to achieve emission targets appeared first on European Pharmaceutical Review.

Pharma 81

Pharma Government Pharmaceutical Healthcare 81

Fierce Pharma

JULY 10, 2023

After a Delaware federal court ruled a Novartis combination patent on big-selling cardiovascular drug Entresto is invalid, the company pledged to continue its efforts to block generics with an appe | After a Delaware district court ruled a 2025 Entresto combination patent is invalid, Novartis will head to the U.S.

188

188

Fierce Pharma

NOVEMBER 30, 2023

22, 2025, pending an FDA approval. As Johnson & Johnson’s top moneymaker Stelara nears its patent cliff, biosimilar makers are eager to launch their own versions of the blockbuster immunology med. Samsung Bioepis' biosimilar, which Sandoz has agreed to commercialize, can launch on Feb.

FDA 130

FDA Marketing 130

pharmaphorum

JANUARY 9, 2023

is to acquire the 2015-established Amryt Pharma Plc. The development is for expansion of the company’s in-house drug development of biologicals and rare disease targeting and the site is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. in an all-cash transaction at $14.50

Pharma 84

Pharma Biopharma Management Medicine 84

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. Pharma is a highly regulated industry and that is often why it is slow to adopt new technologies,” says Kazuki.

Marketing 98

Marketing Pharma Healthcare Healthcare 98

Impetus Digital

JANUARY 13, 2023

The growing role of artificial intelligence (AI) and the importance of the “human aspect” throughout Pharma operations. After more than two years of pandemic restrictions, many Pharma leaders are itching to meet with their key opinion leaders (KOLs) in person again, believing that’s what most KOLs want.

Pharma 94

Pharma Medical Patients Healthcare 94

Clarivate

OCTOBER 31, 2023

These years witnessed significant troughs in pharma financing, a drop in the capital markets, and an IPO window that remained firmly shut. Big pharma is still keen to access good technology, science, and assets, in many cases to plug a patent-expiry-shaped hole in their coffers. In short, the biotech bubble had burst. Pfizer’s $11.6

Pharma 52

Pharma Biopharma Marketing Healthcare 52

Pharma Marketing Network

DECEMBER 17, 2021

Big pharma has compelling reasons to change the way business gets done. Sunny White is an Editorial Advisory Board member for the Pharma Marketing Network with unique insights into how sustainability is moving across the value chain in the pharmaceutical industry. What is Big Pharma doing to tackle climate change? Sunny White.

Pharma 103

Pharma Ethics Recruitment Government 103

Pharmaceutical Technology

NOVEMBER 22, 2022

China will continue to take steps towards becoming as competitive in high-value innovative pharma as it is in the generics industry, with The Wall Street Journal reporting Chinese biotechs raised $1.6tn through 568 venture financings last year, up from $11bn in 418 deals in 2020.

Manufacturing 64

Manufacturing Pharma Government FDA 64

Clarivate

JANUARY 23, 2024

R&D spend is steadily growing and is expected to reach approximately $200 billion by 2025. To learn more about how Clarivate and CMR International help pharmas future-proof their portfolios, please visit us here. The post Pharma R&D productivity dips, but efficiency gains give hope appeared first on Clarivate.

Pharma 52

Pharma Sales Consulting Pharmaceutical 52

PharmaTech

JUNE 14, 2023

The new excipients manufacturing facility is expected to be completed in 2025.

Manufacturing 52

Manufacturing Pharma 52

Fierce Pharma

JUNE 30, 2023

billion) from its Bio CDMO business by March 2025. Fujifilm has tapped a new leader on its quest to deliver 200 billion yen ($1.4 Effective immediately, company veteran Lars Petersen has ascended to the throne as president and chief executive officer of Fujifilm Diosynth Biotechnologies.

130

130

MedCity News

JANUARY 15, 2024

Morgan Healthcare Conference, CEO Joshua Brumm said Dyne’s existing cash combined with the new capital is expected to last through 2025—well beyond the next key milestones for both therapeutic candidates. Dyne Therapeutics recently reported encouraging Phase 1/2 clinical data in myotonic dystrophy type 1 and Duchenne muscular dystrophy.

Medicine 90

Medicine Healthcare Healthcare Biopharma 90

MedCity News

MARCH 11, 2024

Boehringer Ingelheim can exercise its option on the small molecule following a Phase 1 test expected to yield data in 2025. Sosei Heptares’ schizophrenia drug candidate addresses a novel, difficult-to-drug target for neurological disorders.

Biopharma 68

Biopharma Pharma 68

Pharmaceutical Commerce

MARCH 2, 2023

Hoping to accelerate the drug delivery process, production is expected to begin as early as 2025.

Pharma 52

Pharma 52

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8 billion and $1.8

Sales 86

Sales Pharma Government Medicine 86

European Pharmaceutical Review

SEPTEMBER 14, 2023

This includes its Macclesfield campus, the UK’s largest pharma manufacturing site. The pharma company’s sites in Macclesfield, Cambridge, Luton and Speke will be supplied by energy from the biomethane facility. Once operational in early 2025, the partnership will reduce emissions by an estimated 20,000 tonnes CO 2 equivalent (CO 2 e).

Manufacturing 101

Manufacturing Pharmaceutical manufacturing Medicine Pharma 101

European Pharmaceutical Review

NOVEMBER 21, 2023

The pharma company stated that if successful, it has the potential to reduce greenhouse gas emissions from use of the inhaler by approximately 90 percent. Phase III trials of a low carbon version of GSK’s metered dose inhaler, Ventolin (salbutamol), using a next generation, lower carbon propellant, are set to start in 2024.

Manufacturing 107

Manufacturing Patients Pharma Leads 107

European Pharmaceutical Review

NOVEMBER 10, 2023

According to the pharma company , the financing will add to global capacity: from manufacturing of active pharmaceutical ingredients (API) through to packaging. The construction projects will be finalised from the end of 2025 through to 2029. Most of the investment will be focused on API capacity.

Manufacturing 94

Manufacturing Pharmaceutical manufacturing Pharmaceutical Medicine 94

European Pharmaceutical Review

AUGUST 1, 2022

The joint Big Data Steering Group of the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) has published a third workplan, setting actions to be delivered by 2025. According to EMA, the new plan will further enhance the efficient integration of data analysis into the regulatory evaluation of medicinal products.

Medicine 90

Medicine Networking Electronics Healthcare 90

Pharmaceutical Technology

SEPTEMBER 5, 2022

Until 2025, we have strong growth ahead of us, but we also believe we can continue to grow very strongly post-2025 and it’s all about innovation in the pipeline.”. On 23 August, at a Reuters Newsmakers online forum, Soriot announced his interest in increasing AstraZeneca’s portfolio of bolt-on acquisitions leading up to 2025.

FDA 114

FDA Pharmaceutical Biopharma Pharma 114

PM360

OCTOBER 25, 2023

At the heart of this transformation is the role of medical affairs, which is undergoing something of a rebrand as it moves from supporting function to strategic partner within the broader pharma organization. Pharma’s Data Dichotomy Without a doubt, pharma’s primary mission is to create and provide treatments for patients.

Management 105

Management Medical Pharma Pharmaceutical 105

European Pharmaceutical Review

NOVEMBER 23, 2023

This is a first-of-its-kind collaboration for the pharma industry. CPI confirmed that the centre will establish operations during 2024 and be finished in late 2025. Partners include AstraZeneca, GSK, and the University of Strathclyde. The project will be jointly funded by the UK and Scottish Governments.

Manufacturing 82

Manufacturing Medicine Government Pharmaceutical 82

pharmaphorum

AUGUST 17, 2022

It’s part of a larger trend of big pharmas hedging their bets with partnerships with AI firms to find more drug candidates faster. A recent report from GlobalData predicted that pharma spending on AI drug discovery would hit $3 billion in 2025. In 2019 they struck a major deal with China’s Hansoh pharmaceuticals. “At

Medicine 78

Medicine Pharma Engineering Sales 78

pharmaphorum

DECEMBER 22, 2022

The first vaccines are due to be produced at the new facility in 2025. ” ABPI chief executive Richard Torbett said the pharma industry “already invests more than any other sector in R&D in the UK, driving the discovery of the next generation of medicines and vaccines.”

Government 118

Government Manufacturing Sales Medicine 118

European Pharmaceutical Review

SEPTEMBER 26, 2022

The €60 million expansion will open 70 new jobs in sterile manufacturing, quality control and engineering in 2025. Earlier this year, AbbVie was named Best Workplace for Women and ‘Biopharma Company of the Year’ at the latest Irish Pharma Industry Awards. Construction at the Carrigtwohill facility built in 2013 is set to begin in 2023.

Manufacturing 81

Manufacturing Pharmaceutical manufacturing Biopharma Engineering 81

pharmaphorum

JULY 4, 2022

The plan is for the construction of the site to be completed in 2025. Once completed, the site could provide 100,000 square metres of new floorspace for commercial life sciences R&D, according to the pharma group. Construction of the new campus is scheduled to begin next year, and UBS has estimated the site will be worth £1.5

Government 102

Government Media Pharma Management 102

Pharmaceutical Technology

JANUARY 19, 2023

GlobalData’s Pharma Intelligence Center shows 19 autologous CAR-T cell products in Phase I, and nine products in Phase II, globally. Zelenoleucel is being evaluated in the Phase II ARTEMIS trial, and if it demonstrates a benefit over the standard of care arm, it could reach the US market as early as 2025.

Marketing 52

Marketing FDA Sales Management 52

pharmaphorum

NOVEMBER 1, 2022

billion by 2025, growing at a CAGR of 7.5%. Enhance your knowledge of the latest innovations in RNA application and RNA delivery techniques with case studies from BioNTech, Neuway Pharma and Ethris GmbH. LinkedIn: SAE Media Group Pharma. Who should attend: Directors of novel RNA therapies. BOOK BY 3OTH NOVEMBER AND SAVE £200.

Pharmacology 52

Pharmacology Medicine Networking Pharma 52

Pharmaceutical Technology

JULY 21, 2022

Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. In 2020, Fisher & Paykel Healthcare, a medical devices firm, made a SBTi commitment to reduce GHG emissions by 67% by 2034.

Government 52

Government Healthcare Healthcare Pharma 52